ReviewBone marrow transplantation2015
Secondary solid cancer screening following hematopoietic cell transplantation.
Review in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 4 syntheses or guidelines pooled it, 182 citations in OpenAlex.
- Guideline
- MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Guideline
- International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.Transplantation and cellular therapy · 2024Guideline
- Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Pooled it
- Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO-AML Study.Bone marrow transplantation · 2019Trial
- Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation.Blood advances · 2018Trial
- Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2017Trial
- Female allogeneic hematopoietic cell transplant survivors' perspectives on cervical cancer screening: a retrospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Impact of vector copy number on critical quality attributes of retrovirally engineered T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- GD2TNature communications · 2025Article
- Ischemic Heart Disease, Hematological Malignancies, and Infectious Diseases as Risk Factors for Cervical Cancer: A Study Based on Korean National Health Insurance Data.Journal of clinical medicine · 2025Article
- Characteristics of second primary malignancies following bispecific antibodies therapy.Journal for immunotherapy of cancer · 2025Article
- Comparison of oral chronic graft-versus-host disease characteristics between patients with malignant and non-malignant hematopoietic disorders.BMC oral health · 2025Article
- Lorlatinib for the Treatment of Inflammatory Myofibroblastic Tumor after Allogeneic Hematopoietic Stem Cell Transplantation.Internal medicine (Tokyo, Japan) · 2025Article
- Dual α-globin-truncated erythropoietin receptor knockin restores hemoglobin production in α-thalassemia-derived erythroid cells.Cell reports · 2025Article
- Exploring the aftermath of hematopoietic cell transplantation: 18-year insights into post-transplant neoplasms.Frontiers in oncology · 2025Article
- Secondary Esophageal Cancer After Hematopoietic Stem Cell Transplant: An Institutional Case Series.Annals of thoracic surgery short reports · 2024Article
- Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.Transplantation and cellular therapy · 2024Review
- Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry.Blood advances · 2024Article
- Outcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects.Transplantation and cellular therapy · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 20 institutions in 8 countries.
Funding
Abstract
Hematopoietic stem cell transplant (HCT) recipients have a substantial risk of developing secondary solid cancers, particularly beyond 5 years after HCT and without reaching a plateau overtime. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to facilitate implementation of cancer screening appropriate to HCT recipients. The working group reviewed guidelines and methods for cancer screening applicable to the general population and reviewed the incidence and risk factors for secondary cancers after HCT. A consensus approach was used to establish recommendations for individual secondary cancers. The most common sites include oral cavity, skin, breast and thyroid. Risks of cancers are increased after HCT compared with the general population in skin, thyroid, oral cavity, esophagus, liver, nervous system, bone and connective tissues. Myeloablative TBI, young age at HCT, chronic GVHD and prolonged immunosuppressive treatment beyond 24 months were well-documented risk factors for many types of secondary cancers. All HCT recipients should be advised of the risks of secondary cancers annually and encouraged to undergo recommended screening based on their predisposition. Here we propose guidelines to help clinicians in providing screening and preventive care for secondary cancers among HCT recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.